Antares Pharma Inc  

(Public, NASDAQ:ATRS)   Watch this stock  
Find more results for ATRS
+0.03 (1.15%)
After Hours: 2.70 +0.07 (2.66%)
Dec 19, 7:59PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.55 - 2.65
52 week 1.82 - 5.01
Open 2.63
Vol / Avg. 1.86M/1.16M
Mkt cap 339.79M
P/E     -
Div/yield     -
EPS -0.24
Shares 131.68M
Beta 0.48
Inst. own 32%
Mar 11, 2015
Q4 2014 Antares Pharma Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Dec 10, 2014
Antares Pharma Inc at Oppenheimer Healthcare Conference
Dec 2, 2014
Antares Pharma Inc at Piper Jaffray Healthcare Conference
Nov 6, 2014
Q3 2014 Antares Pharma Inc Earnings Release
Nov 6, 2014
Q3 2014 Antares Pharma Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -109.37% -99.46%
Operating margin -109.18% -101.12%
EBITD margin - -98.42%
Return on average assets -36.43% -22.23%
Return on average equity -54.47% -26.08%
Employees 60 -
CDP Score - -


EWING, NJ 08628
United States - Map
+1-609-3593020 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company�s subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices. In the gel-based area, it received Food and Drug Administration (FDA) approval in December 2011 for its oxybutynin gel 3% product, Anturol.

Officers and directors

Leonard S. Jacob M.D., Ph.D Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Eamonn P. Hobbs President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Robert F. Apple CPA Chief Financial Officer, Chief Operating Officer, Executive Vice President, President - Parenteral Products Division
Age: 47
Bio & Compensation  - Reuters
Jennifer Evans Stacey Esq. Senior Vice President, General Counsel, Human Resources and Secretary
Bio & Compensation  - Reuters
Robert P. Roche Jr. Director
Age: 58
Bio & Compensation  - Reuters
Marvin Samson Director
Age: 72
Bio & Compensation  - Reuters
Thomas J. Garrity Independent Director
Age: 65
Bio & Compensation  - Reuters
Jacques Gonella Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Anton G. Gueth Independent Director
Age: 57
Bio & Compensation  - Reuters